Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.repce.2021.10.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association Between Serum Galectin-3 and Parkinson's Disease: A Two-Sample Mendelian Randomization Study.
Brain Behav
October 2024
Department of Neurology, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, P. R. China.
Background: Parkinson's disease (PD) is a prevalent neurodegenerative disorder with poor prognosis. Observational studies have demonstrated a significant correlation between serum galectin-3 and PD, suggesting a potential role of galectin-3 as a biomarker for PD. However, it is still unclear whether galectin-3 contributes to the risk of the disease.
View Article and Find Full Text PDFPaper electrochemical immunosensor for the rapid screening of Galectin-3 patients with heart failure.
Talanta
July 2024
School of Chemistry and Physics, Faculty of Science, Queensland University of Technology (QUT), 2 George Street, Brisbane, QLD, 4000, Australia; Centre for Materials Science, Queensland University of Technology (QUT), 2 George Street, Brisbane, QLD, 4000, Australia; Centre for Biomedical Technology, Queensland University of Technology (QUT), 2 George Street, Brisbane, QLD, 4000, Australia. Electronic address:
A paper electrochemical immunosensor for the combined binding and quantification of the heart failure (HF) biomarker Galectin-3 has been developed. The simple design of the new sensor is comprised of paper material that is decorated with gold nanostructures, to maximize its electroactive surface area, and functionalized with target-specific recognition molecules to selectively bind the protein from aqueous solutions. The binding of the protein caused the blockage of the electron flow to the sensor electroactive surface, thus causing its oxidation potential to shift and the corresponding current to reduce quantitatively with the increase in the protein concentration within the working range of 0.
View Article and Find Full Text PDFResveratrol Alleviates the Early Challenges of Implant-Based Drug Delivery in a Human Glial Cell Model.
Int J Mol Sci
February 2024
Institute of Anatomy, Kiel University, 24118 Kiel, Germany.
Brain diseases are oftentimes life-threatening and difficult to treat. The local administration of drug substances using brain implants can increase on-site concentrations and decrease systemic side effects. However, the biocompatibility of potential brain implant materials needs to be evaluated carefully as implants can trigger foreign body reactions, particularly by increasing the microglia and astrocyte reactivity.
View Article and Find Full Text PDFGalectin-3 (Gal-3) and the tissue inhibitor of matrix metalloproteinase (TIMP-2) as potential biomarkers for the clinical evolution of chronic Chagas cardiomyopathy.
Acta Trop
April 2024
Faculdade de Medicina, Programa de Pós-graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
Background: Chronic Chagas cardiomyopathy (CCC) is responsible for the highest morbidity and worst prognosis in Chagas disease patients. However, predicting factors that correlate with disease progression, morbidity, and mortality is challenging. It is necessary to have simple, quantitative, and economical risk biomarkers that add value to conventional methods and assist in the diagnosis and prognosis of patients with CCC or in evolution.
View Article and Find Full Text PDFSerum Galectin-3 Predicts Mortality in Venoarterial Extracorporeal Membrane Oxygenation Patients.
Cardiol Res Pract
September 2023
Department of Critical Care Medicine, Quannan People's Hospital, Ganzhou 341000, China.
Objective: We investigated the potential use of galectin-3 (Gal-3) as a prognostic indicator for patients with cardiogenic shock and developed a predictive mortality model for venoarterial extracorporeal membrane oxygenation (VA-ECMO).
Methods: We prospectively studied patients (survivors and nonsurvivors) who received VA-ECMO for cardiogenic shock from 2019 to 2021. We recorded baseline data, Gal-3, and B-type natriuretic peptide (BNP) before ECMO and 24-72 h after ECMO.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!